Danaher/$DHR
1D1W1MYTD1Y5YMAX
Capital at risk
About Danaher
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Then, through a series of mergers, acquisitions, and divestitures, Danaher now focuses primarily on manufacturing scientific instruments and consumables in the life sciences and diagnostic industries after the late 2023 divestiture of its environmental and applied solutions group, Veralto.
- Ticker
- $DHR
- Sector
- Health
- Primary listing
- NYSE
- Employees
- 59,000
- Headquarters
- Washington, United States
- Website
- www.danaher.com
Danaher Metrics
BasicAdvanced
$147B
37.16
$5.63
0.80
$1.44
0.76%
Price and volume
Market cap
$147B
Beta
0.8
52-week high
$242.80
52-week low
$160.93
Average daily volume
3.3M
Dividend rate
$1.44
Financial strength
Current ratio
1.651
Quick ratio
1.149
Long term debt to equity
0.503
Total debt to equity
0.53
Dividend payout ratio (TTM)
24.08%
Interest coverage (TTM)
18.83%
Profitability
EBITDA (TTM)
8,028
Gross margin (TTM)
58.75%
Net profit margin (TTM)
15.95%
Operating margin (TTM)
21.89%
Effective tax rate (TTM)
16.21%
Revenue per employee (TTM)
$430,000
Management effectiveness
Return on assets (TTM)
3.95%
Return on equity (TTM)
7.60%
Valuation
Price to earnings (TTM)
37.156
Price to revenue (TTM)
5.902
Price to book
2.8
Price to tangible book (TTM)
-9.09
Price to free cash flow (TTM)
27.11
Free cash flow yield (TTM)
3.69%
Free cash flow per share (TTM)
7.723
Dividend yield (TTM)
0.69%
Forward dividend yield
0.76%
Growth
Revenue change (TTM)
4.56%
Earnings per share change (TTM)
19.57%
3-year revenue growth (CAGR)
2.87%
10-year revenue growth (CAGR)
4.61%
3-year earnings per share growth (CAGR)
-12.88%
10-year earnings per share growth (CAGR)
1.15%
3-year dividend per share growth (CAGR)
11.46%
10-year dividend per share growth (CAGR)
9.33%
What the Analysts think about Danaher
Analyst ratings (Buy, Hold, Sell) for Danaher stock.
Analyst projections of the future price of Danaher stock.
Bulls say / Bears say
Life Sciences delivered 5.5% core growth in the second quarter, its strongest quarter in several years. Management also said large-pharma spending strengthened and biotech funding improved, suggesting the tools-market recovery is broadening. (Danaher)
Danaher raised 2026 adjusted EPS guidance to $8.45–$8.60 and generated $1.3 billion of free cash flow in the second quarter. The early Masimo close and planned StatLab purchase add potentially accretive growth platforms if integration proceeds well. (Danaher, StockTitan)
Bioprocessing revenue is lagging its orders: more than $100 million of shipments have moved from 2026 into 2027. That leaves a real near-term revenue hole and raises questions about how reliably orders convert into sales. (Trefis, Investing.com)
The near-term growth outlook remains modest: Danaher expects only 2%–3% core revenue growth in the third quarter and 3%–4% for the full year. The forecast implies that the hoped-for recovery is still dependent on a second-half acceleration that has yet to be proven. (Danaher)
Diagnostics still faces pricing and volume-based-procurement pressure in China, even though the company says the worst effects are easing. Lower respiratory-testing demand also creates an estimated 250-basis-point headwind in the third quarter, keeping pressure on the segment’s growth and margins. (GoodMoat, Danaher)
Data summarised monthly by Lightyear AI. Last updated on 16 Sept 2026.
Danaher Financial Performance
Revenues and expenses
Danaher Earnings Performance
Company profitability
Upcoming events
Danaher News
AllArticlesVideos
Funds containing Danaher
AllEURGBPUSD
Fund name | Fund size | $DHR weighting |
|---|---|---|
VanEck Morningstar Wide Moat€GMVM | €407M | 2.49% |
VanEck Morningstar Wide Moat£MOGB | £354M | 2.49% |
iShares S&P 500 Health Care Sector€IUHE | €125M | 2.11% |
iShares AI Adopters and Applications€AIAA | €169M | 1.70% |
iShares AI Adopters and Applications£AIAA | £145M | 1.70% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.